Press Releases

    • OCT 09 2017

    Oncoceutics and MD Anderson Expand Alliance to Cover Imipridone ONC212

    Philadelphia, PA (October 9, 2017) – Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center announced the expansion of their strategic alliance and research collaboration agreement to include the clinical development of ONC212. Since 2015, Oncoceutics and MD Anderson have collaborated on the clinical development of ONC201, the founding member of the imipridone

    • SEP 11 2017

    Oncoceutics Begins ONC201 Endometrial Cancer Trial; Receives NIH Grant

    Philadelphia, PA (September 11, 2017) – Oncoceutics, Inc. announced the launch of a clinical trial of ONC201 for patients with recurrent or metastatic endometrial cancer at the Fox Chase Cancer Center. The Phase II trial, being led by Gina Mantia-Smaldone, MD, Assistant Professor in the Department of Surgical Oncology, is listed on ClinicalTrials.gov under NCT03099499

    • AUG 11 2017

    ONC201 Trial for Neuroendocrine Cancer Begins at Cleveland Clinic

    Philadelphia, PA (Aug 9, 2017) – Oncoceutics, Inc. announced today that the first patient has been treated in a Phase II clinical trial of ONC201 for patients with recurrent or metastatic neuroendocrine tumors at the Cleveland Clinic. The selection of neuroendocrine tumors for a clinical trial was driven by the discovery in 2016 that ONC201

    • JUL 10 2017

    Mechanistic Study Uncovers New Utility of ONC201 Mechanism in Lymphoma

    Philadelphia, PA (July 10, 2017) – Oncoceutics, Inc. announced the publication of a scientific manuscript from collaborators at the University of Texas MD Anderson Cancer Center (MDACC) that describes ONC201’s ability to control a set of anti-cancer signaling pathways to induce cell death in tumor, but not  normal cells. The publication, from the laboratory of